Determining Individualized Cancer Therapy In Pancreatic Cancer

Study Overview

Determining Individualized Cancer Therapy in Pancreatic Cancer

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

N/A

Pancreatic Neoplasms

OTHER: Targeted Therapy

PRO00048019

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-06-14	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-04-21
First Submitted that Met QC Criteria 2023-06-14	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-04-24
First Posted (ACTUAL) 2023-06-22	Results First Posted N/A	Last Verified 2025-04

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Number of Subjects Receiving Targeted Therapy	This measure is the number of study subject's whose treating physician prescribes and subsequently receives the therapeutic recommendation of the Molecular Tumor Board.	5 years

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Cancer Center Clinical Trials Office

Phone Number: 1-414-805-8900

Email: cccto@mcw.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Age ≥18 years.
Pathologically confirmed pancreatic cancer.
Ability to understand a written informed consent document and the willingness to sign it

Age <18 years.
Primary cancer diagnosis other than pancreatic cancer.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Mandana Kamgar, MD, Medical College of Wisconsin

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record